Nothing Special   »   [go: up one dir, main page]

AU2021902365A0 - Neutralising antibodies and uses thereof - Google Patents

Neutralising antibodies and uses thereof

Info

Publication number
AU2021902365A0
AU2021902365A0 AU2021902365A AU2021902365A AU2021902365A0 AU 2021902365 A0 AU2021902365 A0 AU 2021902365A0 AU 2021902365 A AU2021902365 A AU 2021902365A AU 2021902365 A AU2021902365 A AU 2021902365A AU 2021902365 A0 AU2021902365 A0 AU 2021902365A0
Authority
AU
Australia
Prior art keywords
neutralising antibodies
neutralising
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021902365A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Melbourne
Original Assignee
University of Melbourne
Filing date
Publication date
Application filed by University of Melbourne filed Critical University of Melbourne
Publication of AU2021902365A0 publication Critical patent/AU2021902365A0/en
Priority to PCT/AU2022/050818 priority Critical patent/WO2023004477A1/en
Abandoned legal-status Critical Current

Links

AU2021902365A 2021-07-30 2021-07-30 Neutralising antibodies and uses thereof Abandoned AU2021902365A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/AU2022/050818 WO2023004477A1 (en) 2021-07-30 2022-07-29 Neutralising antibodies and uses thereof

Publications (1)

Publication Number Publication Date
AU2021902365A0 true AU2021902365A0 (en) 2021-08-12

Family

ID=

Similar Documents

Publication Publication Date Title
EP3740224A4 (en) Anti-lilrb antibodies and uses thereof
EP3762030A4 (en) Anti-cd73 antibodies and uses thereof
EP3918323A4 (en) Anti-gal3 antibodies and uses thereof
EP3891183A4 (en) Anti-claudin antibodies and uses thereof
EP3997127A4 (en) Dll3-targeting antibodies and uses thereof
EP3735427A4 (en) Anti-mct1 antibodies and uses thereof
EP4071172A4 (en) Anti-lilrb1 antibody and uses thereof
EP4139347A4 (en) Anti-cd3 antibodies and uses thereof
EP3962954A4 (en) Anti-galectin-9 antibodies and uses thereof
EP3790586A4 (en) Anti-dll3 antibodies and uses thereof
EP4025609A4 (en) Anti-steap1 antibodies and uses thereof
EP3894440A4 (en) Anti-il-27 antibodies and uses thereof
EP3768317A4 (en) Anti-il-27 antibodies and uses thereof
EP3850012A4 (en) Anti-tnfrsf9 antibodies and uses thereof
EP4001308A4 (en) Anti-tigit antibodies and application thereof
EP3774888A4 (en) Anti-phf-tau antibodies and uses thereof
EP3755714A4 (en) Anti-angiopoietin-2 antibodies and uses thereof
EP4051713A4 (en) Immunomodulatory anti-cd73 antibodies and uses thereof
EP3947462A4 (en) Anti-galectin-9 antibodies and uses thereof
EP4132974A4 (en) Anti-cd98 antibodies and uses thereof
EP4041403A4 (en) Anti-kir3dl3 antibodies and uses thereof
EP4028422A4 (en) Anti-cd371 antibodies and uses thereof
EP4010368A4 (en) Anti-nampt antibodies and uses thereof
EP3894439A4 (en) Anti-periostin antibodies and uses thereof
AU2022298850A1 (en) Anti-ccr8 antibodies and uses thereof